

AMENDMENTS TO THE CLAIMS

1-64 (Cancelled)

65. (Previously presented) An antibody that specifically binds to a polypeptide comprising a sequence set forth in SEQ ID NO:4.

66. (Previously presented) An antibody that specifically binds to a polypeptide selected from the group consisting of a fragment, variant, analog, homolog and derivative of the sequence set forth in SEQ ID NO:4.

67. (Currently amended) An antibody that specifically binds to a polypeptide comprising a fusion protein, said fusion protein comprising a sequence set forth in SEQ ID NO:4.

68. (Previously presented) The antibody according to claim 65, wherein said antibody further comprises a label.

69. (Previously presented) The antibody according to claim 68, wherein said label is selected from the group consisting of an enzyme, protein, peptide, antigen, antibody, lectin, carbohydrate, biotin, avidin, radioisotope, toxin and heavy metal.

70. (Currently amended) ~~An~~ The antibody according to any one of claims 65-69, wherein said antibody is a humanized antibody.

71. (Currently amended) ~~An~~ The antibody according to any one of claims 65-69, wherein said antibody is a CDR-grafted antibody.

72. (Currently amended) ~~An~~ The antibody according to any one of claims 65-69, wherein said antibody is a chimeric antibody.

73. (Currently amended) ~~An~~ The antibody according to any one of claims 65-69, wherein said antibody is an antibody fragment.

74. (Currently amended) ~~An~~ The antibody according to any one of claims 65-69, wherein said antibody is a monoclonal antibody.

75. (New) The antibody according to any one of claims 65-69, wherein said antibody is a polyclonal antibody.

76. (New) A pharmaceutical composition comprising the antibody according to any one of claims 65-69, and a pharmaceutically acceptable adjuvant, diluent, or a carrier.

77. (New) A kit comprising the antibody according to any one of claims 65-69.